Ultragenyx (RARE): Look Through the Noise – A Mid-Term Long Trade Around 2026 Catalysts
Ultragenyx plunged after Phase III setbacks for setrusumab and has since priced in meaningful legal and clinical risk. With a market cap around $2.25B, roughly $1.1B in cash on the balance sheet and an enterprise value of $1.87B, the company can fund operations and pivot while the market digests potential settlement outcomes, upcoming corporate upd…